Janssen - Cilag International — Sponsor Intelligence | 195 EU Trials

Filter these 195 trials by condition, phase, country and more.

Open in Search →

195 Registered trials

60 Recruiting

132 Completed trials

25 Countries active

137 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 79 Phase II/III: 5 Phase II: 33 Phase I/II: 6 Phase IV: 2 Phase I: 28 Phase I (Other): 37 Phase I (FiH): 3 Other: 2

Oversight events:

2 serious breaches 11 temporary halts 5 urgent safety measures 4 unexpected events 5 corrective measures across 16 trials

View oversight register →

100%

132 of 132 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 8 Crohn's disease 7 Prostate cancer metastatic 7 Colorectal cancer 5 Myasthenia gravis 3 Plasma cell myeloma refractory 3 Plasma cell myeloma 3 Myelodysplastic syndrome 3 Dermatitis atopic 2 Prostate cancer recurrent 2 Juvenile psoriatic arthritis 2 Neonatal alloimmune thrombocytopenia 2

Top IMPs

GUSELKUMAB 18 AMIVANTAMAB 15 DEXAMETHASONE 13 NIPOCALIMAB 12 DARATUMUMAB 10 BORTEZOMIB 9 DEXAMETHASONE PH. EUR. 8 JNJ-77242113 8 LAZERTINIB 8 TECLISTAMAB 8 CETRELIMAB 7 ERDAFITINIB 7

All trials

195 total

Comparative Efficacy of Nipocalimab and Efgartigimod in Myasthenia Gravis Study ID: 80202135MYG3002 EPIC Pending

2025-521130-28-00 Phase III 4 countries NIPOCALIMAB
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Pending

2025-523815-12-00 Phase III 7 countries IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURAT…
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting

2025-521590-13-00 Phase III 13 countries GUSELKUMAB; RISANKIZUMAB
A study for adolescents who are depressed and thinking of suicide Recruiting

2024-518615-19-00 Phase III 4 countries ESKETAMINE; MIDAZOLAM
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Phase III 15 countries NIPOCALIMAB
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Phase III 8 countries JNJ-77242113; USTEKINUMAB
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (F… Recruiting

2023-509434-19-00 Phase III 4 countries NIPOCALIMAB
A Phase 1b/2 Study of JNJ-90014496 in Adult Participants with B-cell Non-Hodgkin Lymphoma Recruiting

2023-506267-33-00 Phase I (Other) 6 countries
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Phase III 6 countries JNJ-77242113
A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer Recruiting

2023-504063-17-00 Phase I 2 countries
A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers Recruiting

2023-505165-93-00 Phase I 3 countries
Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neona… Recruiting

2023-504307-88-00 Phase III 10 countries NIPOCALIMAB
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Phase III 6 countries JNJ-77242113
A Phase 1/2 Study of Bleximenib in Participants with Acute Leukemia Recruiting

2023-506581-31-00 Phase I 3 countries BLEXIMENIB; JNJ-75276617
A trial in healthy participants to find out how long JNJ-101556143 stays in and acts on the body when administered as different formulations… Recruiting

2026-526263-38-00 Phase I (Other) 1 country
A Phase 2 Study of JNJ-79635322 in Participants with RRMM Recruiting

2025-521976-80-00 Phase II 2 countries IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURAT…
A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting

2025-522007-18-00 Phase III 7 countries IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURAT…
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Phase III 15 countries NIPOCALIMAB
A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting

2025-523141-10-00 Phase II 5 countries JNJ-88545223
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-522713-29-00 Phase III 5 countries DOCETAXEL; JNJ-78278343; PREDNISONE
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs Recruiting

2025-523297-16-00 Phase I 3 countries
A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC Recruiting

2025-522914-22-00 Phase I (Other) 1 country
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Phase III 12 countries AMIVANTAMAB
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced S… Recruiting

2025-521407-52-00 Phase I 1 country

Showing 1–24 of 195 trials

← All sponsors A–Z